REFERENCES
1. Joerger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol 2015; 11: 691-702.
2. Sonnichsen DS, Hurwitz CA, Pratt CB et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532-538.
3. Karlsson MO, Molnar V, Freijs A et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999; 27: 1220-1223.
4. van Tellingen O, Huizing MT, Panday VR et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81: 330-335.
5. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190.
6. Sykes E, Woodburn K, Decker D, Kessel D. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 1994; 70: 401-404.
7. Sparreboom A, van Zuylen L, Brouwer E et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-1457.
8. Kumar GN, Walle UK, Bhalla KN, Walle T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993; 80: 337-344.
9. Huizing MT, Vermorken JB, Rosing H et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995; 6: 699-704.
10. Wiernik PH, Schwartz EL, Strauman JJ et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-2493.
11. Joerger M, Kraff S, Huitema AD et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51: 607-617.
12. Joerger M, Huitema AD, Huizing MT et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007; 64: 622-633.
13. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16: 1811-1819.
14. Joerger M, Beumer JH. Cancer Treatment in Patients with Hepatic Dysfunction. In: Cancer Treatments in Special Clinical Situations 2013; ESMO Handbook Series.
15. Joerger M, Huitema AD, van den Bongard DH et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 2006; 12: 2150-2157.
16. Miller AA, Rosner GL, Egorin MJ et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 2004; 10: 8325-8331.
17. Mould DR, Fleming GF, Darcy KM, Spriggs D. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol 2006; 62: 56-70.
18. Mielke S, Sparreboom A, Steinberg SM et al. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11: 4843-4850.
19. Huizing MT, Giaccone G, van Warmerdam LJ et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997; 15: 317-329.
20. Joerger M, Huitema AD, Richel DJ et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007; 13: 6410-6418.
21. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 2012; 23 Suppl 10: x313-319.
22. Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012; 38: 613-617.
23. Fountzilas G, Dafni U, Dimopoulos MA et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009; 115: 87-99.
24. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26: 1642-1649.
25. Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-1671.
26. Katsumata N, Yasuda M, Isonishi S et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013; 14: 1020-1026.
27. de Jonge ME, van den Bongard HJ, Huitema AD et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004; 10: 2237-2244.
28. Woo MH, Relling MV, Sonnichsen DS et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5: 543-549.
29. Joerger M, von Pawel J, Kraff S et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27: 1895-1902.
30. Zhang J, Zhou F, Qi H et al. Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol 2019; 85: 2292-2301.
31. Joerger M, Kraff S, Jaehde U et al. Validation of a Commercial Assay and Decision Support Tool for Routine Paclitaxel Therapeutic Drug Monitoring (TDM). Ther Drug Monit 2017; 39: 617-624.
32. Henrich A, Joerger M, Kraff S et al. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. J Pharmacol Exp Ther 2017; 362: 347-358.
33. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
34. Loos WJ, Baker SD, Verweij J et al. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003; 74: 364-371.
35. Joerger M, Beumer JH. Cancer Treatment in Patients with Hepatic Dysfunction. In Cancer Treatments in Special Clinical Situations. ESMO Handbook Series 2013.
36. Bruno R, Olivares R, Berille J et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003; 9: 1077-1082.
37. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-196.
38. Crombag MBS, Dorlo TPC, van der Pan E et al. Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharm Res 2019; 36: 181.
39. de Vries Schultink AHM, Crombag MBS, van Werkhoven E et al. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. Cancer Med 2019; 8: 1406-1415.
40. Franke RM, Carducci MA, Rudek MA et al. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 2010; 28: 4562-4567.
41. Engels FK, Loos WJ, van der Bol JM et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 2011; 17: 353-362.
42. Pean E, Demolis P, Moreau A et al. The European Medicines Agency review of cabazitaxel (Jevtana(R)) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2012; 17: 543-549.
43. Vrignaud P, Semiond D, Lejeune P et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013; 19: 2973-2983.
44. Ferron GM, Dai Y, Semiond D. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013; 71: 681-692.
45. Sarantopoulos J, Mita AC, He A et al. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemother Pharmacol 2017; 79: 339-351.
46. Dieras V, Lortholary A, Laurence V et al. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Eur J Cancer 2013; 49: 25-34.
47. Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 723-730.
48. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
49. Eisenberger M, Hardy-Bessard AC, Kim CS et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 2017; 35: 3198-3206.
50. Janssen A, Verkleij CPM, van der Vlist A et al. Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer. Br J Cancer 2017; 116: 1312-1317.
51. Chen N, Li Y, Ye A et al. Population Pharmacokinetics (PK) and Exposure-Neutropenia Relationship of nab-Paclitaxel (nab-P) in Patients With Solid Tumors. J Clin Oncol 2014; Abstract 2559.
52. Biakhov MY, Kononova GV, Iglesias J et al. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opin Drug Saf 2010; 9: 515-523.
53. Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27: 3611-3619.
54. Socinski MA, Manikhas GM, Stroyakovsky DL et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 852-861.